Brainreader raises €6.6M to expand AI-driven neurological diagnostic platform

Danish medtech company Brainreader has raised €6.6 million to accelerate the global rollout of its AI-driven diagnostic platform Neuroreader. 

Neuroreader is a CE-marked and FDA-cleared software platform that delivers automated volumetric analysis of brain MRI scans. 

Used by radiologists and neurologists in clinical practice, it aids in the diagnosis and monitoring of neurological conditions such as Alzheimer’s disease, traumatic brain injury, and other neurodegenerative disorders.

The technology integrates directly into standard workflows, enabling healthcare professionals to detect subtle changes in brain structure faster and with greater precision.

The round was led by new strategic investor Dahlgren Capital, with continued support from existing shareholder Investo Capital.

The capital injection marks a major milestone for Brainreader as it scales commercial operations, particularly in the US healthcare market, and continues the development of new features and clinical applications.

“This investment allows us to expand faster and reach more clinics worldwide,” says Mads Fiig, CEO of Brainreader.

“Brainreader is building a category-defining solution in AI-enabled brain diagnostics,” says Peter Dahlgren, CEO of Dahlgren Capital. 

Brainreader is well-positioned to capitalise on favourable market dynamics. In the US, the adoption of CPT codes for brain volumetry is creating new reimbursement pathways. In the EU, compliance with Medical Device Regulation (MDR) enables broader clinical use of AI-powered imaging tools across member states.

“We see strong tailwinds for AI in neuroimaging,” adds Thor Birkmand, Chairman of Brainreader and partner at Investo Capital.

 “With this funding and the addition of Dahlgren Capital as an active owner, Brainreader is well-equipped to lead this transformation.”

Lead image: Freepik.